EUVIMEDEUVIMED entdecken
Kohortenstudie

Induction-maintenance intravesical gemcitabine after transurethral resection for intermediate- and selected high-risk non-muscle-invasive bladder cancer: A propensity score-matched cohort study

Junqing Gu

Pakistan Journal of Pharmaceutical Sciences · 19.11.2026

DOI: 10.36721/pjps/2026.40.16893.1 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pakistan Journal of Pharmaceutical Sciences, online erschienen am 19.11.2026. Verfasst von Junqing Gu. Die Arbeit nennt 25 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Conventional intravesical chemotherapeutic agents for non-muscle-invasive bladder cancer (NMIBC) are limited by drug resistance and local adverse reactions, which may restrict their clinical benefit.

Objectives

This study aimed to evaluate the clinical efficacy, urinary and serum concentration indicators, safety and exploratory pharmacoeconomic value of induction-maintenance intravesical gemcitabine as postoperative adjuvant therapy for intermediate- and selected high-risk NMIBC.

Methods

A retrospective propensity score-matched cohort design was used. A total of 294 patients with intermediate- and selected high-risk NMIBC who underwent transurethral resection of bladder tumor from January 2022 to October 2023 were screened and follow-up records were reviewed through 31 October 2025. After 1:1 nearest-neighbor matching, 100 patients were retained in the induction-maintenance intravesical gemcitabine group and 100 in the conventional intravesical mitomycin group; tumor recurrence, recurrence-free survival, urinary and serum concentration indicators, adverse events and direct medical costs were compared between the two groups.

Results

The tumor recurrence rates at 12 and 24 months were lower in the gemcitabine group than in the mitomycin group (p=0.008) and the mean recurrence-free survival time was longer in the gemcitabine group (p

Zitieren

APA

Gu, J. (2026). Induction-maintenance intravesical gemcitabine after transurethral resection for intermediate- and selected high-risk non-muscle-invasive bladder cancer: A propensity score-matched cohort study. Pakistan Journal of Pharmaceutical Sciences. https://doi.org/10.36721/pjps/2026.40.16893.1

Vancouver

Gu J. Induction-maintenance intravesical gemcitabine after transurethral resection for intermediate- and selected high-risk non-muscle-invasive bladder cancer: A propensity score-matched cohort study. Pakistan Journal of Pharmaceutical Sciences. 2026. doi:10.36721/pjps/2026.40.16893.1

BibTeX
@article{Gu2026,
  author = {Gu, Junqing},
  title = {Induction-maintenance intravesical gemcitabine after transurethral resection for intermediate- and selected high-risk non-muscle-invasive bladder cancer: A propensity score-matched cohort study},
  journal = {Pakistan Journal of Pharmaceutical Sciences},
  year = {2026},
  doi = {10.36721/pjps/2026.40.16893.1}
}
Kostenlos starten →